Iovance Biotherapeutics Inc. Stock
Iovance Biotherapeutics Inc. took a tumble today and lost -€0.560 (-4.310%).
Our community is currently high on Iovance Biotherapeutics Inc. with 19 Buy predictions and 3 Sell predictions.
Based on the current price of 12.47 € the target price of 25 € shows a potential of 100.56% for Iovance Biotherapeutics Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Iovance Biotherapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Iovance Biotherapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Iovance Biotherapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc. | -4.310% | 17.799% | 4.082% | 109.285% | 66.560% | -44.518% | - |
| Ironwood Pharmaceuticals | 0.680% | 2.069% | -1.333% | -23.711% | -27.451% | -18.681% | - |
| Sage Therapeutics Inc. | 0.040% | -7.586% | -20.370% | -70.585% | -39.700% | -79.833% | - |
| Novocure Ltd | 3.290% | 25.795% | 13.841% | -76.180% | 1.121% | -90.875% | - |
Comments
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $21.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Barclays PLC from $18.00 to $22.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat